Niagen Bioscience
NAGE
58 hedge funds and large institutions have $51.2M invested in Niagen Bioscience in 2019 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 16 increasing their positions, 14 reducing their positions, and 6 closing their positions.
54% more call options, than puts
Call options by funds: $106K | Put options by funds: $69K
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
21% more capital invested
Capital invested by funds: $42.2M → $51.2M (+$9.04M)
14% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 14
1.64% more ownership
Funds ownership: 18.21% → 19.86% (+1.6%)
0% more funds holding
Funds holding: 58 → 58 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UIC
Uniplan Investment Counsel
Milwaukee,
Wisconsin
|
+$3.01M |
| 2 |
BlackRock
New York
|
+$1.27M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$421K |
| 4 |
TCM
Tieton Capital Management
Yakima,
Washington
|
+$276K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$163K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIP
Granite Investment Partners
El Segundo,
California
|
-$334K |
| 2 |
Invesco
Atlanta,
Georgia
|
-$282K |
| 3 |
Morgan Stanley
New York
|
-$224K |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$132K |
| 5 |
MML Investors Services
Springfield,
Massachusetts
|
-$94K |
NAGE Hedge Fund Activity: Q2 2019 in Review
58 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q2 2019, worth a combined $51.2M — up 21% from $42.2M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new NAGE positions and 6 closed out — a net gain of 2 holders — while 16 added to existing stakes and 14 trimmed.
The largest buyer was Uniplan Investment Counsel, opening a new position worth an estimated $3.01M. The largest seller was Granite Investment Partners, cutting an estimated $334K.
- 58 institutional investors held Niagen Bioscience (NAGE) as of Q2 2019, unchanged from Q1 2019.
- Funds reported $51.2M of Niagen Bioscience stock for Q2 2019, up 21% quarter-over-quarter.
- 8 funds opened new Niagen Bioscience positions in Q2 2019 and 6 closed out, a net change of +2 holders.
- The largest Niagen Bioscience buyer in Q2 2019 was Uniplan Investment Counsel, an estimated $3.01M added.
- The largest Niagen Bioscience seller in Q2 2019 was Granite Investment Partners, an estimated $334K sold.
Based on aggregated 13F filings for Q2 2019.